-
1Academic Journal
Authors: L. S. Kruglova, A. A. Hotko
Source: Качественная клиническая практика, Vol 0, Iss 1, Pp 46-55 (2021)
Subject Terms: число госпитализаций, количество обращений за амбулаторной помощью, псориаз, количество листов временной нетрудоспособности, дней временной нетрудоспособности, 3. Good health, генно-инженерная биологическая терапия, RS1-441, 03 medical and health sciences, Pharmacy and materia medica, 0302 clinical medicine, псориатический артрит, длительность госпитализаций, Medical technology, R855-855.5
Access URL: https://www.clinvest.ru/jour/article/download/562/574
https://doaj.org/article/9fa04cbb6b0142e0878259f5feb9a98f
https://www.clinvest.ru/jour/article/download/562/574
https://cyberleninka.ru/article/n/resursopotreblenie-i-trudosposobnost-patsientov-na-fone-primeneniya-sistemnoy-terapii-i-genno-inzhenernoy-biologicheskoy-terapii/pdf
https://www.clinvest.ru/jour/article/view/562/574
https://cyberleninka.ru/article/n/resursopotreblenie-i-trudosposobnost-patsientov-na-fone-primeneniya-sistemnoy-terapii-i-genno-inzhenernoy-biologicheskoy-terapii -
2Academic Journal
Authors: article Editorial, статья Редакционная
Contributors: Опубликовано с разрешения правообладателя John Wiley & Sons, Ltd
Source: Safety and Risk of Pharmacotherapy; Том 10, № 3 (2022); 315-316 ; Безопасность и риск фармакотерапии; Том 10, № 3 (2022); 315-316 ; 2619-1164 ; 2312-7821
Subject Terms: Кокрейновский обзор, medication errors, adverse drug event, electronic prescribing systems, barcode identification, adult patients, length of hospital stay, quality of life, evidence, Cochrane review, ошибки, неблагоприятное лекарственное событие, электронные системы назначений, штрихкодирование, взрослые пациенты, длительность госпитализации, качество жизни, доказательства
File Description: application/pdf
Relation: https://www.risksafety.ru/jour/article/view/330/564; https://www.risksafety.ru/jour/article/downloadSuppFile/330/267; https://www.risksafety.ru/jour/article/view/330
-
3Academic Journal
Authors: S. K. Zyryanov, O. I. Butranova, A. V. Ershov, Z. Sh. Manasova, С. К. Зырянов, О. И. Бутранова, А. В. Ершов, З. Ш. Манасова
Source: Meditsinskiy sovet = Medical Council; № 18 (2021); 106-117 ; Медицинский Совет; № 18 (2021); 106-117 ; 2658-5790 ; 2079-701X
Subject Terms: септические осложнения, azoximer bromide, duration of hospital stay, septic complications, азоксимера бромид, длительность госпитализации
File Description: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/6559/5944; Torres A., Peetermans W.E., Viegi G., Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013;68(11):1057-1065. https://doi.org/10.1136/thoraxjnl-2013-204282.; Theilacker C., Sprenger R., Leverkus F., Walker J., Hackl D., von Eiff C., Schiffner-Rohe J. Population-based incidence and mortality of community-acquired pneumonia in Germany. PLoS ONE. 2021;16(6):e0253118. https://doi.org/10.1371/journal.pone.0253118.; Partouche H., Lepoutre A., Vaure C.B.D., Poisson T., Toubiana L., Gilberg S. Incidence of all-cause adult community-acquired pneumonia in primary care settings in France. Med Mal Infect. 2018;48(6):389-395. https://doi.org/10.1016/j.medmal.2018.02.012.; Lopardo G.D., Fridman D., Raimondo E., Albornoz H., Lopardo A., Bagnulo H. et al. Incidence rate of community-acquired pneumonia in adults: a population-based prospective active surveillance study in three cities in South America. BMJ Open. 2018;8(4):e019439. Available at: https://pub-med.ncbi.nlm.nih.gov/29643153/.; McLaughlin J.M., Khan F.L., Thoburn E.A., Isturiz R.E., Swerdlow D.L. Rates of hospitalization for community-acquired pneumonia among US adults: A systematic review. Vaccine. 2020;38(4):741-751. https://doi.org/10.1016/j.vaccine.2019.10.101.; Metlay J.P., Waterer G.W., Long A.C., Anzueto A., Brozek J., Crothers K. et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67. https://doi.org/10.1164/rccm.201908-1581ST.; Tansarli G.S., Mylonakis E. Systematic Review and Meta-analysis of the Efficacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia in Adults. Antimicrob Agents Chemother. 2018;62(9):e00635-e00718. https://doi.org/10.1128/AAC.00635-18.; Marshall D.C., Goodson R.J., Xu Y., Komorowski M., Shalhoub J., Maruthappu M., Salciccioli J.D. Trends in mortality from pneumonia in the Europe union: a temporal analysis of the European detailed mortality database between 2001 and 2014. Respir Res. 2018;19(1):81. https://doi.org/10.1186/s12931-018-0781-4.; Rendon A., Rendon-Ramirez E.J., Rosas-Taraco A.G. Relevant Cytokines in the Management of Community-Acquired Pneumonia. Curr Infect Dis Rep. 2016;18(3):10. https://doi.org/10.1007/s11908-016-0516-y.; International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies, Notarangelo L.D., Fischer A., Geha R.S., Casanova J.L, Chapel H., Conley M.E. et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol. 2009;124(6):1161-1178. https://doi.org/10.1016/j.jaci.2009.10.013.; de la Torre M.C., BoUbar I., Vendrell M., de Gracia J., Vendrell E., Rodrigo M.J. et al. Serum immunoglobulins in the infected and convalescent phases in community-acquired pneumonia. Respir Med. 2013;107(12):2038-2045. https://doi.org/10.1016/j.rmed.2013.09.005.; Trabattoni D., Clerici M., Centanni S., Mantero M., Garziano M., Blasi F. Immunomodulatory effects of pidotimod in adults with community-acquired pneumonia undergoing standard antibiotic therapy. Pulm Pharmacol Ther. 2017;44:24-29. https://doi.org/10.1016/j.pupt.2017.03.005.; Welte T., Dellinger R.P., Ebelt H., Ferrer M., Opal S.M., Singer M. et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Med. 2018;44(4):438-448. https://doi.org/10.1007/s00134-018-5143-7.; Петров Р.В., Хаитов Р.М., Некрасов А.В., Атаулаханов Р.И., Пинегин Б.В., Пучкова А.С. и др. Полиоксидоний - иммуномодулятор последнего поколения: итоги трехлетнего клинического применения. Аллергия, астма и клиническая иммунология. 1999;(3):3-6.; Dyakonova V.A., Dambaeva S.V., Pinegin B.V., Khaitov R.M. Study of interaction between the polyoxidonium immunomodulator and the human immune system cells. Int Immunopharmacol. 2004;4(13):1615-1623. https://doi.org/10.1016/j.intimp.2004.07.015.; Toptygina A., Semikina E., Alioshkin V. Influence of an immunopotentiator Polyoxidonium on cytokine profile and antibody production in children vaccinated with Priorix. Arch Physiol Biochem. 2012;118(4):197-203. https://doi.org/10.3109/13813455.2012.659669.; Alexia C., Cren M., Louis-Plence P., Vo D.N., El Ahmadi Y., Dufourcq-Lopez E. et al. Polyoxidonium® Activates Cytotoxic Lymphocyte Responses Through Dendritic Cell Maturation: Clinical Effects in Breast Cancer. Front Immunol. 2019;10:2693. https://doi.org/10.3389/fimmu.2019.02693.; Grivtsova L.Y., Falaleeva N.A., Tupitsyn N.N. Azoximer Bromide: Mystery, Serendipity, and Promise. Front Oncol. 2021;11:699546. https://doi.org/10.3389/fonc.2021.699546.; Efimov S.V., Matsiyeuskaya N.V., Boytsova O.V., Akhieva L.Y., Kvasova E.I., Harrison F. et al. The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study. Drugs Context. 2021;10:2020-11-1. https://doi.org/10.7573/dic.2020-11-1.; Синопальников А.И. Американские (atS/idSa, 2019) и российские (РРо/ МакМах, 2019) рекомендации по ведению внебольничной пневмонии у взрослых. Два взгляда на актуальную проблему. Consilium Medicum. 2020;22(3):22-27. https://doi.org/10.26442/20751753.2020.3.200084.; Чучалин А.Г., Синопальников А.И., Козлов Р.С., Авдеев С.Н., Тюрин И.Е., Руднов В.А. Внебольничная пневмония: клинические рекомендации. 2018. М.; 2018. 98 с. Режим доступа: https://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii/.; Cabre M., Bolivar I., Pera G., Pallares R., Pneumonia Study Collaborative Group. Factors influencing length of hospital stay in community-acquired pneumonia: a study in 27 community hospitals. Epidemiol Infect. 2004;132(5):821-829. https://doi.org/10.1017/s0950268804002651.; Suter-Widmer I., Christ-Crain M., Zimmerli W., Albrich W., Mueller B., Schuetz Ph. Predictors for length of hospital stay in patients with community-acquired pneumonia: results from a Swiss multicenter study. BMC Pulm Med. 2012;12:21. https://doi.org/10.1186/1471-2466-12-21.; Kozma C.M., Dickson M., Raut M.K., Mody S., Fisher A.C., Schein J.R., Mackowiak J.I. Economic benefit of a 1-day reduction in hospital stay for community-acquired pneumonia (CAP).J Med Econ. 2010;13(4):719-727. https://doi.org/10.3111/13696998.2010.536350.; Tellioglu E., Balci G., Mertoglu A. Duration of Stay of Patients with Community-Acquired Pneumonia in Influenza Season. Turk Thorac J. 2018;19(4):182-186. https://doi.org/10.5152/TurkThoracJ.2018.17108.; Ostermann H., Garau J., Medina J., Pascual E., McBride K., Blasi F., REACH study group. Resource use by patients hospitalized with community-acquired pneumonia in Europe: analysis of the REACH study. BMC Pulm Med. 2014;14:36. https://doi.org/10.1186/1471-2466-14-36.; Walden A.P., Clarke G.M., McKechnie S., Hutton P., Gordon A.C., Rello J. et al. Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort. Crit Care. 2014;18(2):R58. https://doi.org/10.1186/cc13812.; Angus D.C., Marrie T.J., Obrosky D.S., Clermont G., Dremsizov T.T., Coley C. et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med. 2002;166(5):717-723. https://doi.org/10.1164/rccm.2102084.; Mbata G., Chukwuka C., Onyedum C., Onwubere B., Aguwa E. The role of complications of community acquired pneumonia on the outcome of the illness: a prospective observational study in a tertiary institution in eastern Nigeria. Ann Med Health Sci Res. 2013;3(3):365-369. Available at: https://pubmed.ncbi.nlm.nih.gov/24116315/.; Kolditz M., Ewig S. Community-Acquired Pneumonia in Adults. Dtsch Arztebl Int. 2017;114(49):838-848. https://doi.org/10.3238/arztebl.2017.0838.; Jain S., Self W.H., Wunderink R.G., Fakhran S., Balk R., Bramley A.M. et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015;373(5):415-427. https://doi.org/10.1056/NEJMoa1500245.; Kolditz M.,Tesch F., Mocke L., Hoffken G., Ewig S., Schmitt J. Burden and risk factors of ambulatory or hospitalized CAP: A population based cohort study. Respir Med. 2016;121:32-38. https://doi.org/10.1016/j.rmed.2016.10.015.; Maskin B., Fontan P.A., Spinedi E.G., Gammella D., Badolati A. Evaluation of endotoxin release and cytokine production induced by antibiotics in patients with Gram-negative nosocomial pneumonia. Crit Care Med. 2002;30(2):349-354. https://doi.org/10.1097/00003246-200202000-00014.; Hurley J.C. Towards clinical applications of anti-endotoxin antibodies; a reappraisal of the disconnect. Toxins (Basel). 2013;5(12):2589-2620. https://doi.org/10.3390/toxins5122589.; Bosshart H., Heinzelmann M. Targeting bacterial endotoxin: two sides of a coin. Ann N Y Acad Sci. 2007;1096:1-17. https://doi.org/10.1196/annals.1397.064.; Kritselis I., Tzanetakou V., Adamis G., Anthopoulos G., Antoniadou E., Bristianou M. et al. The level of endotoxemia in sepsis varies in relation to the underlying infection: Impact on final outcome. Immunol Lett. 2013;152(2):167-172. https://doi.org/10.1016/j.imlet.2013.05.013.; Мавзютова Г.А., Мухамадиева Л.Р., Фазлыева Р.М., Мирсаева Г.Х., Тюрина Е.Б. Рациональная иммунокоррекция в комплексной терапии внебольничной пневмонии. Медицинский совет. 2015;(16):68-73. https://doi.org/10.21518/2079-701X-2015-16-68-73.; Мухамадиева Л.Р, Мавзютова ГА., Фазлыева Р.М., Бикметова Н.Р Клиникоиммунологическая эффективность имунофана и полиоксидония в комплексной терапии внебольничной пневмонии. Медицинская иммунология. 2009;11(1):57-62. https://doi.org/10.15789/1563-0625-2009-1-57-62.
-
4Academic Journal
Authors: A. K. Nosov, S. A. Reva, I. B. Dzhalilov, S. B. Petrov, А. К. Носов, С. А. Рева, И. Б. Джалилов, С. Б. Петров
Source: Cancer Urology; Том 11, № 3 (2015); 71-78 ; Онкоурология; Том 11, № 3 (2015); 71-78 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2015-11-3
Subject Terms: длительность госпитализации, radical cystectomy, laparoscopic cystectomy, video-assisted cystectomy, open-access cystectomy, hemotransfusion, intraoperative bleeding conduit, complications, length of hospital stay, радикальная цистэктомия, лапароскопическая цистэктомия, видеоассистированная цистэктомия, открытая цистэктомия, кондуит, осложнения, интраоперационная кровопотеря, гемотрансфузия
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/491/457; Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2012. 260 с. [Malignant neoplasm in Russia in 2010 (morbidity and mortality). Ed. V. Chissov,V. Starinsky, G. Petrova. Moscow, 2012. 260 p. (In Russ.)].; Lawrentschuk N., Colombo R., Hakenberg O.W. et al. Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol 2010;57:983–1001.; Hollenbeck B.K., Miller D.C., Taub D. et al. Identifying risk factors for potentially avoidable complications following radical cystectomy. J Urol 2005;174:1231–7.; Shabsigh A., Korets R., Vora K.C. et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methology. Eur Urol 2009;55:164–76.; Chang S.S., Cookson M.S., Baumgartner M.G. et al. Analysis of early complications after radical cystectomy: results of a collaborative care pathway. J Urol 2002;167:2012–6.; Johnson D.E., Lamy S.M. Complications of a single stage radical cystectomy and ileal conduit diversion: review of 214 cases. J Urol 1977;117:171–3.; Skinner D.G., Crawford E.D., Kaufman J.J. Complications of radical cystectomy for carcinoma of the bladder. J Urol 1980;123:649–53.; Thomas D.M., Riddle P.R. Morbidity and mortality in 100 consecutive radical cystectomies. Br J Urol 1982;54:716–9.; Daneshmand S., Ahmadi H., Schuckman A.K. et al. Enhanced recovery after surgery in patients undergoing radical cystectomy for bladder cancer. J Urol 2014;192(1):50–6.; Hautmann R.E., Abol-Enein H., Davidsson T. et al. ICUD-EAU International Consultation on Bladder Cancer 2012: urinary diversion. Eur Urol 2013;(63):67–80.; Menon M., Hemal A.K., Tewari A. et al. Nerve-sparing robot-assisted radical cystprostatectomy and urinary diversion. BJU Int 2003;92(3):232–6.; Challacombe B.J., Bochner B.H., Dasgupta P. et al. The role of laparoscopic and robotic cystectomy in the management of muscle-invasive bladder cancer with special emphasis on cancer control and complications. Eur Urol 2011;60(4):767–75.; Smith A.B., Raynor M., Amling C.L. et al. Multi-institutional analysis of robotic radical cystectomy for bladder cancer: periopetative outcomes and complications in 227 patients. J Laparoendosc Adv Surg Tech A 2012;22:17–21.; Паршин А.Г. Радикальная цистэктомия с отведением мочи в сегмент подвздошной кишки: результаты и осложнения (клиническое исследование). Автореф. дис. … канд. мед. наук. 2004. 159 с. [Parshin A.G. Radical cystectomy withurine diversion to ileum segment: results and complications (clinical study). Synopsis of thesis … of Ph.D. Med. 2004;159 p. (In Russ.)].; Stenzl A., Cowan N.C., De Santis M. et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59(6):1009–18.; Somani B.K., Gimlin D., Fauers P., N’dow J. Quality of life and body image for bladder cancer patients undergoing radical cystectomy and urinary diversion – a prospective cohort study with a systematuc review of literature. Urology 2009;74: 1138–43.; Philip J., Manikandan R., Venugopal S. et al. Orthotopic neobladder versus ileal conduit urinary diversion after cystectomy – a quality-of-life based comparison. Ann R Coll Surg Engl 2009;91:565–9.; Петров С.Б., Левковский Н.С., Король В.Д., Паршин А.Г. Радикальная цистэктомия как основной метод лечения мышечно-инвазивного рака мочевого пузыря (показания, особенности техники, профилактика осложнений). Практическая онкология 2003;4(4):225–30. [Petrov S.B., Levkovskiy N.S., Korol V.D., Parshin A.G. Radical cystectomy as the main method of muscular invasive bladder cancer (indications, special features of procedure, prevention of complications). Prakticheskaya onkologiya = Practical Oncology 2003;4(4):225–30. (In Russ.)].; Gill I.S., Kaouk J.H., Meraney A.M. et al. Laparoscopic radical cystectomy and continent orthotopic ileal neobladder performed completely intracorporeally: the initial experience. J Urol 2002;168: 13–8.; Dindo D., Demartines N., Clavien P.A. Classification of surgical complications. A new propisal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2005;240:205–13.; Martin II R.C., Brennan M.F., Jaques D.P. Quality of complication reporting in the surgical literature. Ann Surg 2002;235:803–13.; Azzouni F.S., Din R., Rehman S. et al. The first 100 consecutive, robot-assisted, intracorporeal ileal conduits: evolution of technique and 90-day outcomes. Eur Urol 2014;63(4):637–43.; Huang J., Lin T., Liu H. et al. Laparoscopic radical cystectomy with orthotopoic ileal neobladder for bladder cancer: oncologic result of 171 cases with a median 3-year follow- p. Eur Urol 2010;58(3):442–9.; Ng C.K., Kauffman E.C., Lee M.M. et al. A comparison of postoperative complications in open versus robotic cystectomy. Eur Urol 2010;57(2):274–81.; Hendrickson J.E., Hillyer C.D. Noninfectious serious hazards of transfusion. Anesth Analg 2009;108:759–69.; Kox M.L., El-Galley R., Busby G.E. Robotic versus open radical cystectomy: identification of patients who benefit from the robotic approach. J Endourol 2013;27:40–4.; Castillo O.A., Abreu S.C., Mariano M.B. et al. Complications in laparoscopic radical cystectomy. The South American experience with 59 cases. Int Braz J Urol 2006;32(3):300–5.; Ramirez J.A., McIntosh A.G., Strehlow R. et al. Definition, incidence, risk factors and prevention of paralytic ileus following radical cystectomy: a systematic review. Eur Urol 2013;64(4):588–97.; Chang S.S., Baumgartner R.G., Wells N. et al. Causes of increased hospital stay after radical cystectomy in a clinical pathway setting. J Urol 2002;167:208–11.; Anderson C.B., Morgan T.M., Kappa S. et al. Ureteroenteric anastomotic strictures after radical cystectomy - does operative approach matter? J Urol 2013;189(2):541–7.; Albisinni S., Limani K., Ingels L. et al.Long-term evaluation of oncologic and functional outcomes after laparoscopic openassisted radical cystectomy: a matched-pair analysis. World J Urol 2014, in press.; Madersbacher S., Schmidt J., Eberle J.M. et al. Long-term outcome of ileal conduit. J Urol 2003;169(3):985–90.; https://oncourology.abvpress.ru/oncur/article/view/491
-
5Academic Journal
Authors: G. N. Alekseeva, L. I. Gurina, B. V. Mazalov, A. G. Filippov, M. V. Volkov, Г. Н. Алексеева, Л. И. Гурина, Б. В. Мазалов, А. Г. Филиппов, М. В. Волков
Source: Cancer Urology; Том 11, № 1 (2015); 20-25 ; Онкоурология; Том 11, № 1 (2015); 20-25 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2015-11-1
Subject Terms: выживаемость, surgical treatment, nephrectomy, organ-sparing surgery, resection, surgical complications, hospital length of stay, amount of blood loss, therapy, renal ischemia, survival rate, хирургическое лечение, нефрэктомия, органосохраняющая операция, резекция, хирургические осложнения, длительность госпитализации, объем кровопотери, ишемия почки
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/413/423; https://oncourology.abvpress.ru/oncur/article/view/413/480; Злокачественные новообразования в России в 2012 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2014. 250 с. [Malignant neoplasms in Russia in 2012 (morbidity and mortality). Ed. A.D. Caprin, V.V. Starinskiy, G.V. Petrova. M., 2014. 250 p. (In Russ.)]; Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.; Матвеев Б.П. Опухоли почечной паренхимы. В кн.: Клиническая онкоурология. Под ред. Б.П. Матвеева. М.: АБВ-пресс, 2011. С. 11–225. [Matveev B.P. Tumors of the renal parenchyma. In: Clinical oncourology. Ed. B.P. Matveev. M.: ABV-press, 2011. P. 11–225. (In Russ.)]; Волкова М.И., Скворцов И.Я., Климов А.В. и др. Влияние объема хирургического вмешательства на функциональные результаты и кардиоспецифическую выживаемость у больных клинически локализованным раком почки. Онкоурология 2014;3:22–30. [Volkova, M.I., Skvortsov I.J., Klimov A.V. et al. Influence of surgical intervention on functional outcome and survival in cardiac patients clinically localized renal cell carcinoma. Onkourologija = Oncourology 2014;3:22–30. (In Russ.)].; Аляев Ю.Г., Глыбочко П.В., Григорян З.Г. Органосохраняющие операции при опухоли почки. М.: ГЭОТАР-Медиа, 2009. 272 с. [Alyaev J.G. Ablative surgery for kidney tumors. Alyaev J.G., Glybochko P.V., Grigoryan Z.G. et al. M.: GEOTAR–Media, 2009. 272 p. (In Russ.)]; Long C.J., Canter D. J., Kutikov A. et al. Partial nephrectomy for renal masses ≥ 7 cm: technical, oncological and functional outcomes. BJU Int 2012;109:1450–6.; Amit R., Patel A.R., Eggener S.E. Warm ischemia less than 30 minutes is not necessarily safe during partial nephrectomy: every minute matters. Urol Oncol 2011;29(6):826–8.; Khed M., Bellec L., Leobon B. et al. Partial nephrectomy by selective renal parenchymal clamping using a new clamp. Prog Urol 2007;17(1):41–4.; Clavien P.A., Barkun J., de Oliviera M.L. et al. The Clavien-Dindo classification of surgical complications: Five-year experience. Ann Surg 2009;250:187–96.; Есаян А.М., Аль-Шукри С.Х., Мосоян М.С. Почечно-клеточный рак и хроническая болезнь почек: внимание к отдаленным неонкологическим исходам. Нефрология 2012;16(4):94–9. [Yesayan A.M., Al-Shukri S.H., Mosoyan M.S. Renal cell carcinoma and chronic kidney disease: attention to remote non-cancer outcomes. Nephrology 2012;16(4):94–9.; Van Poppel H., Pozzo Da L., Albrecht W. A prospektive, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephronsparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol2011;59:543–52.; Kim S.P. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol 2012;188(1):51–7.; Weight C.J., Lieser G., Larson B.T. et al. Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumors. Eur Urol 2010;58: 293–8.; Аполихин О.И., Чернышев И.В., Павлов Д.А. и др. Тенденции развития эндовидеохирургии локализованного рака почки. Мат-лы XIV конгресса РОУ. Саратов, 2014 г. С. 247–248. [Apolikhin O.I., Chernyshev I.V., Pavlov D.A. et al. Development trends endovideosurgery localized kidney cancer. Proceedings of the XIV Congress of the ROU. Saratov, 2014. Р. 247–248 (In Russ.)].; Leibovich B.C., Blute M.L., Cheville J.C. et al. Prediction of progression afte radical nefrectomy for patients with clear cell renal cell carcinoma: a stratification tooll for prospective clinical trials. Cancer 2003;97(7):1663–71. URL: http://www.ncbi.nlm.nih.gov./pub. med./1265523.; Thompson R.H., Lane B.R., Lohse C.M. et al. Every minute counts when the renal hilum is clamped during partial nephrectomy. Eur Urol 2010;58:340–5.; Gill I.S., Patil M.B., de Castro Abreu A.L. et al. Zero ischemia anatomical partial nephrectomy: a novel approach. J Urol 2012;187(3):807–15.; Матвеев В.Б., Комаров И.Г., Волкова М.И. и др. Безопасность и целесообразность использования трансперитонеального лапароскопического доступа для выполнения радикальной нефрэктомии при клинически локализованном раке почки. Онкоурология 2013;4:14–21. [Matveev V.B., Komarov I.G., Volkova M.I. et al. Safety and usefulness of the transperitoneal laparoscopic approach for performing radical nephrectomy for clinically localized renal cancer. Onkourologija = Oncourology 2013;4:14–21. (In Russ.)].; Алексеев Б.Я., Калпинский А.С., Нюшко К.М. и др. Анализ непосредственных результатов органосохраняющего лечения у больных раком почки: сравнение лапароскопической резекции почки с резекцией почки открытым способом. Мат-лы VII конгресса РООУ. М., 2012. С. 132– 133. [Alekseev B.J., Kalpinsky A.S., Nyushko K.M. et al. Analysis of the immediate results of organ-preserving treatment in patients with renal cell carcinoma: a comparison of LPN with open partial nephrectomy way. Proceedings of the VII Congress ROOU. M., 2012. Р. 132– 133. (In Russ.)].; https://oncourology.abvpress.ru/oncur/article/view/413
-
6Academic Journal
Authors: Волошин, Алексей, Лядов, К., Кирюшин, Д., Мукуца, И., Серебряков, А.
Subject Terms: ЭНДОПРОТЕЗИРОВАНИЕ СУСТАВОВ, МУЛЬТИМОДАЛЬНАЯ АНАЛЬГЕЗИЯ, СЛУЖБА ЛЕЧЕНИЯ БОЛИ, КОНТРОЛИРУЕМАЯ ПАЦИЕНТОМ АНАЛЬГЕЗИЯ, ИНТЕНСИВНОСТЬ БОЛИ, ДЛИТЕЛЬНОСТЬ ГОСПИТАЛИЗАЦИИ
File Description: text/html
-
7Academic Journal
Authors: Lobzin S.V., Mirzaeva L.M.
Source: Marine Medicine; Vol 6, No 1 (2020); 33-42 ; Морская медицина; Vol 6, No 1 (2020); 33-42 ; 2587-7828 ; 2413-5747 ; 10.22328/2413-5747-2020-6-1
Subject Terms: marine medicine, spinal cord injury, complications, length of hospital stay, corticosteroids, морская медицина, травма спинного мозга, осложнения, длительность госпитализации, кортикостероиды
File Description: application/pdf
-
8Academic Journal
Authors: Зырянов С.К., Бутранова О.И., Ершов А.В., Манасова З.Ш.
Source: Meditsinskiy Sovet
Subject Terms: community-acquired pneumonia, azoximer bromide, duration of hospital stay, septic complications, внебольничная пневмония, азоксимера бромид, длительность госпитализации, септические осложнения
Availability: https://repository.rudn.ru/records/article/record/90723/
